AmpliPhi BioSciences (formerly Targeted Genetics) has announced that it has raised approximately $13,000,000 in a private placement financing that it will use for three development programs.
The company’s lead candidate, AmpliPhage-001, is an inhaled bacteriophage for the treatment of P. aeruginosa lung infections in cystic fibrosis patients. According to the company, it plans to complete inhalation toxicology studies of AmpliPhage-001 by the end of 2015.
AmpliPhi is partnered with Intrexon on development of several bacteriophages and has received funding from the Cystic Fibrosis Foundation for the AmpliPhage-001 program.
AmpliPhi Chairman and Interim CEO Jeremy Curnock Cook commented, “AmpliPhi is looking forward to an exciting 2015 as our programs approach the clinic. This financing round provides the necessary capital to advance our phage therapy programs into clinical trials. Together with our world-class partners, which include notable research institutions and our strategic collaborator Intrexon Corporation, we are well positioned to finally realize the potential of phage-based therapies to make a key contribution to addressing the global need for alternative therapies that address the potentially devastating effects of drug resistant infections.”
Read the AmpliPhi Biosciences press release.
